Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

(2010) Jianming Zhang et al.   NATURE

Ubiquitin C-Terminal Electrophiles Are Activity-Based Probes for Identification and Mechanistic Study of Ubiquitin Conjugating Machinery

(2009) Kerry Routenberg Love et al.   ACS Chemical Biology

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

The emerging complexity of protein ubiquitination

(2009) David Komander   BIOCHEMICAL SOCIETY TRANSACTIONS

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and SuppressesIn vitroResistance

(2009) Mohammad Azam et al.   Chemical Biology & Drug Design

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

(2009) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

Linkage-Specific Avidity Defines the Lysine 63-Linked Polyubiquitin-Binding Preference of Rap80

(2009) Joshua J. Sims et al.   MOLECULAR CELL

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

Targeting proteins for degradation

(2009) Erin K Schrader et al.   Nature Chemical Biology

Regulation of hematopoiesis by the K63-specific ubiquitin-conjugating enzyme Ubc13

(2009) X. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Charting the molecular network of the drug target Bcr-Abl

(2009) M. Brehme et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells

(2008) Ling-Yuan Kong et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation

(2008) A. Rodriguez-Gonzalez et al.   CANCER RESEARCH

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53

(2008) Saurabh Dayal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute